DexCom, Inc. (DXCM) EVP Andrew K. Balo Sells 5,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the company’s stock in a transaction on Friday, October 12th. The shares were sold at an average price of $124.79, for a total transaction of $623,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Andrew K. Balo also recently made the following trade(s):

  • On Friday, September 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $145.17, for a total transaction of $725,850.00.
  • On Tuesday, August 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $124.25, for a total transaction of $621,250.00.

DXCM stock opened at $133.20 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. DexCom, Inc. has a 52 week low of $43.74 and a 52 week high of $148.56. The stock has a market capitalization of $12.64 billion, a P/E ratio of -229.66 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The business had revenue of $242.50 million for the quarter, compared to the consensus estimate of $205.81 million. During the same period in the prior year, the company posted ($0.16) earnings per share. DexCom’s revenue was up 42.1% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post -0.47 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. Morgan Stanley lifted its position in DexCom by 16.3% during the second quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after purchasing an additional 705,072 shares during the period. Victory Capital Management Inc. lifted its position in DexCom by 67,520.1% during the second quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock worth $46,948,000 after purchasing an additional 493,572 shares during the period. Waddell & Reed Financial Inc. lifted its position in DexCom by 164.8% during the second quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after purchasing an additional 354,331 shares during the period. Columbus Circle Investors lifted its position in DexCom by 192.3% during the second quarter. Columbus Circle Investors now owns 532,489 shares of the medical device company’s stock worth $50,576,000 after purchasing an additional 350,339 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in DexCom by 25.1% during the second quarter. Point72 Asset Management L.P. now owns 1,225,344 shares of the medical device company’s stock worth $116,383,000 after purchasing an additional 246,169 shares during the period.

Several research firms have commented on DXCM. Morgan Stanley upped their price objective on shares of DexCom from $130.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. BidaskClub downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday, October 3rd. Northland Securities upgraded shares of DexCom from an “under perform” rating to a “market perform” rating in a research note on Wednesday, September 12th. Robert W. Baird upped their price target on shares of DexCom from $140.00 to $160.00 and gave the company a “positive” rating in a research note on Thursday, August 23rd. Finally, Stephens upped their price target on shares of DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a research note on Thursday, August 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. DexCom has a consensus rating of “Buy” and an average target price of $123.13.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Stock Split

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply